Depression in COPD – management and quality of life considerations by Stage, Kurt B et al.
International Journal of COPD 2006:1(3) 315–320
© 2006 Dove Medical Press Limited. All rights reserved
315
REVIEW
Abstract: Depression is common in COPD patients. Around 40% are affected by severe 
depressive symptoms or clinical depression. It is not easy to diagnose depression in COPD 
patients because of overlapping symptoms between COPD and depression. However, the six-
item Hamilton Depression Subscale appears to be a useful screening tool. Quality of life is 
strongly impaired in COPD patients and patients’ quality of life emerges to be more correlated 
with the presence of depressive symptoms than with the severity of COPD. Nortriptyline and 
imipramine are effective in the treatment of depression, but little is known about the usefulness 
of newer antidepressants. In patients with milder depression, pulmonary rehabilitation as well 
as cognitive-behavioral therapy are effective. Little is known about the long-term outcome in 
COPD patients with co-morbid depression. Preliminary data suggest that co-morbid depression 
may be an independent protector for mortality.
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Introduction
It is recognized that many physical illnesses may have a direct link to the appearance 
of depressive syndromes and many studies have documented a high rate of depression 
and anxiety among patients suffering from COPD (Yellowlees et al 1987; Karajgi et al 
1990; van Ede et al 1999; Aghanwa and Erhabor 2001; Dowson et al 2001; Mikkelsen 
et al. 2004). COPD is a severe treatment-resistant pulmonary disease with varying 
impact on the patient’s general physical condition, functioning, and quality of life. It 
is assumed that a successful treatment of a co-morbid depression leads to improved 
quality of life and less restricted general functioning (Rodin et al 1991). However, 
the evaluation of psychopathology in medical patients, eg, those with COPD, presents 
special problems. Almost all self-report and clinicians’ rating scales for detecting 
depression is biased by a large number of items dealing with somatic symptoms. For 
example, the Hamilton Depression Scale (Ham-D) (Hamilton 1960; Hamilton 1967) 
has eight or nine items reﬂ  ecting somatic complaints or changes in somatic functioning. 
Such items are also included in the ofﬁ  cial diagnostic criteria for depression, ie, ICD-
10 (WHO 1992) and DSM-IV (APA 1994). Therefore, it is difﬁ  cult to decide when 
these somatic symptoms are secondary to depression and when they are a secondary 
to the somatic illness.
This review will focus on our knowledge about epidemiology, diagnostic 
procedures, treatment aspects, and quality of life in COPD patients with co-morbid 
depression. We will also summarize recent ﬁ  ndings concerning how the interaction 
between depression and COPD may affect patients’ survival.
Prevalence and co-morbidity
The prevalence of depressive symptoms in COPD patients varies considerably. Two 
recent reviews (van Ede et al 1999; Mikkelsen et al 2004) found a prevalence of 
depression, ranging from 6% to 57%. 
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Van Ede et al (1999) found a prevalence ranging from 
6% to 42%. They emphasized that only 4 out of 34 studies 
had a control group (McSweeny et al 1982; Prigatano et al 
1984; Isoaho et al 1995; Engstrom et al 1996). However, all 
four studies showed that the prevalence was higher in the 
study group, ie, the COPD patients, but the difference was 
statistically signiﬁ  cant in two of the studies only (McSweeny 
et al 1982; Prigatano et al 1984). 
Mikkelsen et al (2004) pointed out that two of the latest 
prevalence studies identiﬁ  ed clinically signiﬁ  cant depressive 
symptoms in 42%–57% of COPD patients (Yohannes et al 
2000; Lacasse et al 2001). The major co-morbidity studies 
are summarized in Table 1.
There are many possible explanations for these differing 
results. Many studies are performed on small samples and are 
lacking control groups. The way the psychiatric diagnoses 
are obtained also varies. Some studies utilize established 
diagnostic criteria, other studies only use clinical assessments 
or self-reported symptoms. Most studies contain no formal 
data analysis and only simple descriptive statistics. Finally, 
differences in the objective characteristics and severity 
of COPD may contribute to the variations in prevalence 
ﬁ  gures.
In summary, the prevalence of depression is high 
in COPD patients, for both occurrence of “significant 
symptoms” and clinical depression. Although there are large 
variations in prevalence ﬁ  gures, the latest studies point out 
a prevalence of more than 40% (Yohannes et al 2000; Stage 
et al 2003).
Quality of life
According to McSweeny et al (1982), quality of life is 
concerned with the following four dimensions: emotional 
functioning, social-role functioning, activities of daily living 
(ADL), and recreational pastimes.
Compared with persons without physical illness, COPD 
patients have impaired quality of life (McSweeny et al 1982; 
Prigatano et al 1984; Yohannes et al 1998).
COPD patients with co-morbid depression have impaired 
quality of life compared with COPD patients without 
depression (Bosley et al 1996; Yohannes et al 1998; Kim 
et al 2000; Aydin and Ulusahin 2001; Felker et al 2001; 
Yohannes et al 2003). Yohannes et al (2003) also showed 
that COPD patients’ quality of life was more correlated to 
the presence of depressive symptoms than to the severity 
of COPD as measured by FEV1. This phenomenon was 
also demonstrated by Kim et al (2000). In a different study 
28 patients were followed over 4 years, but even though their 
physical condition got better because of aggressive medical 
treatment, no improvement in quality of life was shown (van 
Schayck 1997).
In spite of this, co-morbid depression does not seem to 
worsen the physical aspects of COPD (Light et al 1985; 
Borak et al 1998). For example Light et al (1985) found 
no signiﬁ  cant correlation between the level of depression 
or anxiety and the distance that the patient could walk in 
12 minutes.
Diagnostic aspects
Today, the ICD-10 and DSM-IV criteria for depression 
are the most common diagnostic tools. When it comes 
to depression in patients with severe somatic illness, the 
validity of the ICD-10 and DSM-IV criteria for depression 
may to a certain degree be questioned because it is difﬁ  cult 
to decide when somatic symptoms are secondary to 
depression and when they are secondary to somatic illness. 
In fact, the ICD-10 has a general exclusion criterion that the 
depressive episode is not attributed to any organic cause, 
while the DSM-III-R/IV is less restrictive on the matter. 
Severe COPD could lead to somatic symptoms impossible 
to separate from depressive symptoms. Endicott (1984) has 
therefore suggested replacement of the somatic symptoms 
in the DSM-III-R/IV criteria with alternative non-somatic 
depressive symptoms, ie, replace change in appetite–weight 
with tearfulness–depressed appearance, sleep disturbances 
with social withdrawal, fatigue or loss of energy with 
brooding–pessimism, and diminished ability to think or 
concentrate with lack of reactivity to environmental events. 
These modiﬁ  cations have to some extent been validated 
(Rapp and Vrana 1989; Kathol et al 1990) and may be 
they should be used when trying to identify depression in 
subjects with somatic illness. However, as long as there 
is no method for deciding whether the somatic symptoms 
are secondary to depression or COPD, the classiﬁ  cation 
will be biased.
In a recent study, we tested the internal and external 
validity of the six-item Hamilton Depression subscale 
(HAM-D-6) in a sample of 49 COPD patients (Stage et al 
2003). We found that HAM-D-6 could be used as a screening 
instrument for depression in COPD patients, ie, the sensitivity 
of the test was 0.91, the speciﬁ  city was 0.88, the positive 
predictive value 0.87, and the negative predictive value 
was 0.91 when the cut-off score was set to 7 or more on 
HAM-D-6. The HAM-D-6 items are shown in Table 2. If 
the HAM-D-6 total score is 10 or more, treatment with an 
antidepressant is often required.International Journal of COPD 2006:1(3) 317
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Treatment of depression in COPD 
patients
Antidepressants
The tricyclic antidepressants (TCAs) have been tested 
in a few studies (Light et al 1986; Sharma et al 1988; 
Borson et al 1992). Although the results are contradictory, 
there is some evidence that TCAs are effective. Borson 
et al (1998) studied 30 patients who completed a 12-
week, randomized, controlled trial of nortriptyline. 
Nortriptyline was clearly superior to placebo for treatment 
of depression. Nortriptyline treatment was accompanied 
by marked improvements in anxiety, certain respiratory 
symptoms, overall physical comfort, and day-to-day 
function; placebo effects were negligible. Physiological 
measures reflecting pulmonary insufficiency were 
generally unaffected by treatment. It has also been shown 
that imipramine in combination with diazpam is effective 
(Sharma et al 1988), while doxepine failed in a placebo-
controlled trial (Light et al 1986). Table 3 shows treatment 
information about imipramine and nortriptyline. Note that 
Table 1 Summary of co-morbidity studies: Prevalence of psychiatric co-morbidity in COPD patients
Author   Sample/control  group    Psychiatric assessment methods   Findings    
McSweeny et al 1982    203 COPD, nocturnal oxygen treatment    Self-report:  Depression 42% in COPD  vs 9% in 
  73 healthy controls (HC)     MMPI  POMS, SIP   HC   
Prigatano et al 1984    985 COPD outpatients   Self  report:   No  prevalence  ﬁ   gures. 
 25  HC   POMS,  SIP    POMS anxiety and depression score 
      signiﬁ  cantly higher in COPD group 
Yellowlees et al 1987    50 COPD inpatients with exacerbation   Psychiatric  interview:    Panic anxiety 24% 
   DSM-III  diagnoses    Generalized anxiety 10% 
     Depression  12% 
Karajgi et al 1990    50 COPD outpatients   Psychiatric  interview:    Anxiety disorders 16% 
   DSM-III  diagnoses    Mood disorders 8% 
Isoaho et al 1995    82 COPD community sample   Self-report:    Depression, men 26% vs 18% 
 246  HC   Zung  Depression  Scale     Depression, women 33% vs 20%,
       Differences non-signiﬁ  cant 
Engstrøm et al 1996    68 COPD in- and outpatients   Self-report:    Depression 7% vs 1% 
 89  HC   HADS    Anxiety 13% vs 6% 
     Differences  signiﬁ   cant 
Yohannes et al 2000    137 COPD outpatients    Psychiatric interview and   Clinical depression in 42%   2/3 of 
   self-report:   MADRS  these patients moderately depressed 
     Geriatric Mental Health Scale    (MADRS) 
Dowson et al 2001    79 COPD inpatients   Self-report:  HADS   Depression  28% 
     Anxiety  50% 
Lacasse et al 2001    109 COPD, home care   Self-report:    Depressive symptoms 57% 
   SF-36 
   GDS   
Aghanwa and   30 COPD outpatients    Self report and interview:    Depression 16.7% anxiety 10% in 
Erhabor 2001   30  hypertensive  patients   GHQ-30   COPD  group
 30  HC   PSE      Signiﬁ  cantly less in control groups 
Aydin and Ulusahin 2001    38 COPD inpatients   Self  report:    Depression and/or anxiety 47.3%
 120  tuberculosis  patients   GHQ-12     Prevalence 19%–26% in control 
     group
     Differences  signiﬁ   cant 
Stage et al 2003    49 COPD outpatients   Psychiatric  interview:    Major depression 33% 
   ICD-10  diagnoses    Mild depression 14% 
    Hamilton Rating Scales for 
    anxiety and depression   
Abbreviations: GDS, Geriatric Depression Scale; GHQ, General Health Questioner; HADS, Hospital Anxiety and Depression Scale; HC, healthy controls; MADRS, 
Montgomery-Asberg Rating Scale; MMPI, Minnesota Multiphasic Personality Intervention; POMS, Proﬁ  le of Mood States; SIP, Sickness Impact Proﬁ  le.
Table 2 The six-item Hamilton Depression subscale 
(HAM-D-6)
1. Depressed  mood
2. Guilt  feelings
3.  Work and interest
4. Retardation
5. Psychic  anxiety
6. General  somaticInternational Journal of COPD 2006:1(3) 318
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the doses of imipramine and nortriptyline are lower than 
in patients without co-morbid COPD, mainly because 
most COPD patients are elderly. Treating elderly patients 
with TCAs like imipramine and nortriptyline is not 
unproblematic due to an increased risk of severe side-
effects. The decision to start a TCA treatment balances 
the documented efficacy and the increased risk of side- 
effects in elderly patients.
Little is known about the effectiveness of newer 
antidepressants like the selective serotonin reuptake inhibitors 
(SSRIs) but smaller studies and case reports suggests that 
SSRIs are well tolerated although the compliance may be 
poor (Papp et al 1995; Smoller et al 1998; Yohannes et al 
2001).
Benzodiazepines and other drugs
Benzodiazepines have anxiolytic effect in COPD patients 
(Nutt et al 1999), but may cause respiratory depression. 
Therefore, benzodiazepines should be considered only if 
other anxiolytic agents have failed.
Buspirone has been tested in COPD patients, but the 
results are not conclusive (Argyropoulou et al 1993; Singh 
et al 1993).
Non-pharmacological treatment
In general the non-pharmocological treatment of depression 
in COPD is limited to patients with milder depression and 
here multidisciplinary pulmonary rehabilitation as well 
as cognitive-behavioral therapy (CBT) appears effective 
(Borson et al 1998).
CBT for this group of patients includes increasing the 
patients’ body-awareness by exercises in relaxation and 
breathing. The cognitive elements of the treatment are 
aimed at identifying automatic thoughts and promote a 
more adaptive cognitive style. Graduated exposure and 
desensitizing is then attempted to reduce fears of symptoms 
as well as alleviating the panic reactions. Eiser et al (1997) 
found that six sessions of CBT resulted in sustained 
improvement in exercise tolerance in patients suffering from 
severe COPD and anxiety. In a recent randomized clinical 
trial (Kunik et al 2001), a single 2-hour session of group 
CBT and weekly calls over 6 weeks reduced both depressed 
mood and anxiety. The effect was signiﬁ  cantly better than 
in the control group (2-hour education and weekly calls). 
There were no improvements in physical functioning in 
either group.
Pulmonary rehabilitation programs have also been 
described for COPD patients for co-morbid anxiety and 
depression. By means of progressive exercise, training 
of respiratory function, and psycho-education, patients 
obtained better exercise tolerance, less dyspnea, and 
better quality of life (Ries et al 1995; Emery et al 1998; 
Withers et al 1999; de Godoy and de Godoy 2003; Garuti 
et al 2003).
Table 3 Treatment information about the tricyclic antidepressants (TCAs) imipramine and nortriptyline: the decision to start a TCA 
treatment balances the documented efﬁ  cacy and the increased risk of side-effects in elderly patients
Effect    Better than placebo in randomized controlled trials   
Dose in elderly patients   Imipramine:  50–100 mg/day 
 Nortriptyline:  25–75 mg/day   
  Start low – go slow!   
Recommended plasma   Imipramine (plus desipramine): 175–350 ng/ml 
levels at steady state   Nortriptyline:  50–150 ng/ml   
Examples of common   Orthostatic hypotension (less common with nortriptyline), dizziness, tachycardia, dry mouth, blurred vision, 
side-effects      disturbance of accommodation, constipation, and drowsiness   
Examples of less common   Arrhythmias, heart block, confusional states, seizures, urinary retention, paralytic ileus, drug fever, skin rash, bone
side-effects    marrow depression, altered liver function, hypomania, and falls.   Increased mortality in patients with ischemic heart 
  disease. Pre-existing heart block gets worse during treatment   
Pre-treatment examinations   Physical  examination 
  Measurement of orthostatic hypotension 
 ECG  Blood tests including liver enzymes   
Table 3: Key points
￿  Around 40% of all COPD patients have severe depressive symptoms or clinical depression
￿  The six-item Hamilton Depression Subscale seems to be a useful screening tool
￿  Quality of life is strongly impaired in COPD patients and is more correlated with the presence of depressive symptoms than to the severity of COPD
￿  Nortriptyline, imipramine, pulmonary rehabilitation. and cognitive-behavioral therapy are effective treatment options
￿  Preliminary data suggest that co-morbid depression may be an independent protector for mortality
￿  Much more research is needed in this ﬁ  eldInternational Journal of COPD 2006:1(3) 319
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Does depression affect the long-
term outcome in COPD patients?
Few studies have examined the long-term outcome of 
depressed COPD patients. Yet we recently published a study 
focusing on the survival in COPD patients (Stage et al 2005). 
We found that co-morbid depression signiﬁ  cantly reduced 
the mortality risk at follow-up. The impact of depression 
remained after control for FEV1, the only multivariate 
signiﬁ  cant predictor of mortality in the data set (hazard 
ratio, 0.27; 95% conﬁ  dence interval, 0.09–0.84; p=0.024). 
The cumulative mortality for depressed and non-depressed 
COPD patients is shown in Figure 1. We concluded that 
depression appears to be an independent protector for 
mortality, although we have no clues about the underlying 
mechanism. However, the study included only 49 patients 
and it should be replicated in a larger sample. 
Conclusion
Depression is very common in COPD patients. Around 
40% are affected by severe depressive symptoms or clinical 
depressions. It is not easy to diagnose depression in COPD 
patients because of the overlapping symptoms between 
COPD and depression. However, the six-item Hamilton 
Depression Subscale (HAM-D-6) appears to be a useful 
screening tool. Quality of life is strongly impaired in COPD 
patients and patients’ quality of life emerges to be more 
correlated with the presence of depressive symptoms than 
with the severity of COPD. Nortriptyline and imipramine 
are effective in the treatment of depression, but little is 
known about the usefulness of newer antidepressants. In 
patients with milder depressionm, pulmonary rehabilitation 
as well as cognitive-behavioral therapy seem effective. Little 
is known about the long-term outcome in COPD patients 
with co-morbid depression. Preliminary data suggest that 
co-morbid depression may be an independent protector for 
mortality.
Much more research is needed concerning epidemiology, 
psychopathology, quality of life, treatment, and long-term 
outcome. 
The key points of this review are shown in Table 3.
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